title: An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA.
abstract: Histone deacetylase (HDAC) inhibitors are used in treating certain human malignancies. Our laboratories demonstrated their capability in enhancing antitumor effect of DNA vaccine driven by an RNA polymerase II (RNA pol II) promoter. However, it is unknown whether HDAC inhibitors enhance the therapeutic short hairpin RNA (shRNA) expressed by an RNA polymerase III (RNA pol III) promoter. We investigated whether HDAC inhibitors augmented antitumor effect of indoleamine 2,3 dioxygenase (IDO) shRNA. HDAC inhibitor OSU-HDAC42 and suberoylanilide hydroxamic acid enhanced RNA pol III-driven U6 and H1 promoter activity in three different cell types in vitro: 293, NIH3T3 and dendritic cell line DC2.4. Subcutaneous injection of OSU-HDAC42 enhanced U6 and H1 promoter activity on abdominal skin of mice in vivo. Combination of IDO shRNA and OSU-HDAC42 increased antitumor effect of IDO shRNA in MBT-2 murine bladder tumor model. IDO shRNA induced tumor-infiltrating CD8⁺ and CD4⁺ T cells, whereas OSU-HDAC42 treatment induced tumor-infiltrating CD4⁺ T cells. Combination of OSU-HDAC42 and IDO shRNA further induced tumor-infiltrating natural killer cells and enhanced interferon-γ in lymphocytes, but suppressed interleukin (IL)-4 expression of lymphocytes. In addition, OSU-HDAC42 treatment did not alter mRNA expression of IL-12 and tumor necrosis factor-α. In conclusion, HDAC inhibitor OSU-HDAC42 may serve as adjuvant of the therapeutic shRNA expressed by an RNA pol III promoter.
authors.affiliation: Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
authors.forename: M-C
authors.initials: MC
authors.lastname: Yen
authors.forename: T-Y
authors.initials: TY
authors.lastname: Weng
authors.forename: Y-L
authors.initials: YL
authors.lastname: Chen
authors.forename: C-C
authors.initials: CC
authors.lastname: Lin
authors.forename: C-Y
authors.initials: CY
authors.lastname: Chen
authors.forename: C-Y
authors.initials: CY
authors.lastname: Wang
authors.forename: H-L
authors.initials: HL
authors.lastname: Chao
authors.forename: C-S
authors.initials: CS
authors.lastname: Chen
authors.forename: M-D
authors.initials: MD
authors.lastname: Lai
mesh_terms: D000818:Animals; D003713:Dendritic Cells / Q000187:drug effects; D004357:Drug Synergism; D006655:Histone Deacetylases / Q000235:genetics / Q000378:metabolism; D006801:Humans; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000235:genetics / Q000378:metabolism; D051379:Mice; D041681:NIH 3T3 Cells; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D010654:Phenylbutyrates / Q000008:administration & dosage*; D011401:Promoter Regions, Genetic / Q000187:drug effects; D012320:RNA Polymerase III / Q000235:genetics*; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000235:genetics; D019444:Vaccines, DNA / Q000008:administration & dosage*
chemical_list: D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; C529674:OSU-HDAC42 compound; D010654:Phenylbutyrates; D034741:RNA, Small Interfering; D019444:Vaccines, DNA; D012320:RNA Polymerase III; D006655:Histone Deacetylases